Active Biotech
0.556 SEK +2.96%Be the first to follow this company
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ACTI
Daily low / high price
0.54 / 0.57
SEK
Market cap
201.13M SEK
Turnover
130.25K SEK
Volume
235K
Latest videos
Financial calendar
Interim report
08.05.2024
General meeting
22.05.2024
Interim report
22.08.2024
Interim report
07.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
MGA Holding AB | 28.1 % | 28.1 % |
Sjuenda Holding | 7.4 % | 7.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Annual Report 2023 Active Biotech AB (publ)
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools